Introduction to Journal of Leukemia and Lymphoma
The journal of leukemia and lymphoma (monthly) was founded in 1992 with the title of Shanxi Leukemia; Leukemia. Lymphoma; Leukemia. This journal is an academic journal specialized in hematological malignancies, mainly including leukemia, lymphoma and multiple myeloma. The purpose of the journal: to reflect the scientific research achievements and academic trends in the field of hematological malignancy, and to develop both clinical and basic research, but focus on clinical research; Both popularization and improvement should be considered, but the emphasis should be on improvement. It provides a forum for exchange of experience and information for workers engaged in basic research and clinical diagnosis and treatment of hematological malignancies such as leukemia, lymphoma and multiple myeloma. Readers are middle and senior medical workers.
Column setting of leukemia and lymphoma magazine
Essays, experimental studies, clinical studies, investigation reports, seat counting, reviews, monographs, short stories and case reports.
Honorary Information of Leukemia&Lymphoma Journal
Leukemia · Lymphoma magazine subscription
Address: No. 3, Gongyexin Street, Taiyuan City, 030013.
Notice to contributors of Leukemia&Lymphoma Magazine
1. The contributions should be credible, clear argument, clear hierarchy, concise writing, clear printing or neat writing. Basic research, clinical research, review and lectures generally do not exceed 4000 words, clinical experience does not exceed 3000 words, and short stories and case reports do not exceed 1500 words (all contain figures, tables and references).
2. Basic research and clinical research manuscripts must be attached with Chinese and English abstracts. The abstracts should be structured in such a way that the four elements of purpose, method, result and conclusion are complete. 200-400 words are preferred, and each part should be titled accordingly. The results should contain necessary data information; English abstract corresponds to Chinese. The English abstract (to be printed) shall include the title, the name of the author (Chinese phonetic alphabet), the name of the company, the name of the city and the zip code. Clinical experience is required to attach 1 Chinese structured abstract of less than 200 words, and summary and lecture categories are required to attach indicative abstract and corresponding English abstract.
3. Each manuscript should be marked with 3-5 Chinese and English keywords. Please use the subject words in the latest version of MesH Glossary edited by the National Library of Medicine as far as possible. The Chinese translation name shall be marked according to the Chinese Thesaurus, the Annotated Word Order List of Medical Thesaurus or the latest version of English Chinese Medical Vocabulary. The main free words or important words of new disciplines and new technologies not included in the thesaurus can be used as keywords.
4. References are limited to major new literature that has been read in person, especially the literature of the past two years. One to three authors of the cited literature are listed, and more than three authors are listed only in the top three, followed by "etc." or other corresponding words. Abbreviations shall be used for the names of foreign periodicals, which shall be subject to the format in IndexMedicus, and full names shall be used for Chinese periodicals. English references are required to be printed in the following format.
[Journal] Author. Title [J]. Title. Year, Volume (Issue): Start Page - End Page
[Book] Author. Title [M]. Volume. Edition. Place of Publication: Publisher, Year: From Page to Page
5. If the subject involved in the paper has obtained national or ministerial or provincial funding or is a key research project, the footnote should be at the bottom left of the title page.
6. Submissions must be reviewed and approved by the author's unit, and a letter of recommendation from the unit must be attached. Indicate the first author's detailed address, postal code, telephone number and e-mail. All contributions are now submitted online. Those who have not received notice within 6 months after receiving the receipt of this journal are still in the process of review and research. If the author submits to another journal, please write to contact this journal. This magazine generally does not reject manuscripts. The author is requested to keep the manuscript.
7. The manuscript processing fee must be paid when submitting the manuscript (50 yuan for more than 1500 words, 30 yuan for less than 1500 words, please remit it through the post office, and do not include the manuscript). Any subscriber who holds a copy of the order can be exempted from the manuscript processing fee, and the layout fee will be appropriately reduced when the manuscript is published.
8. All research papers supported by NSFC and approved by scientific research projects can be published preferentially if they submit certificates.
9. This journal is included in Wanfang and other databases, and the author's copyright royalties and the journal's remuneration are paid in a lump sum. Once a manuscript is published, it will be paid and a copy of the current magazine will be presented.
10. The copyright of this journal belongs to the Chinese Medical Association. Any paper published in this journal is deemed that the author agrees to grant the exclusive right to use the paper to the Chinese Medical Association. The Chinese Medical Association has no objection to the use of this article in electronic journals (CD version, online version). Without the consent of the Chinese Medical Association, no part of this article may be reproduced elsewhere.
Example of Leukemia&Lymphoma Journal
A Case of Floral Nucleus Acute B-Lymphocyte Leukemia
Therapeutic effect of preactivated psoralen on leukemia transplanted tumor in nude mice
Expression and mutation of tumor suppressor gene Rox in leukemia cells
In vitro mechanism of histone deacetylase inhibitor on B-cell lymphoma
Detection of prognostic specific protein mass spectrometry in diffuse large B-cell lymphoma by SELDI
Imatinib combined with allogeneic hematopoietic stem cell transplantation in the treatment of acute lymphoblastic transformation of chronic myeloid leukemia
Telomerase activity, multidrug resistance and prognosis in refractory leukemia
Maintenance chemotherapy after autologous hematopoietic stem cell transplantation for acute myeloid leukemia
Clinical characteristics of acute leukemia in the elderly
Chemotherapy based on nordoxorubicin in the treatment of acute leukemia
Expression of mucin 1 gene in leukemia and its clinical significance
Changes and Significance of TF, TFPI, t-PA and PAI-1 in Acute Leukemia
Primary non Hodgkin's lymphoma of bone: report of 10 cases
Molecular biological efficacy of arsenious acid based regimen in the treatment of acute promyelocytic leukemia
Clinical study of erythropoietin receptor and fas antigen expression in bone marrow erythroblasts of patients with tumor anemia
Maintenance treatment of acute promyelocytic leukemia with all trans retinoic acid, 6-mercaptopurine and methotrexate
18 cases of primary central nervous system lymphoma
Treatment of 29 cases of refractory myeloid leukemia with nordoxorubicin
Dual induction therapy with AA and TA regimen in 12 patients with refractory acute myeloid leukemia
Modified Bu CTX2 Preconditioning Peripheral Blood Stem Cell Transplantation for Hematological Tumor
